Den Europæiske Union - engelsk - EMA (European Medicines Agency)

seqirus gmbh - influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain(a/brisbane/10/2010, wild type)a/switzerland/9715293/2013 (h3n2) - like strain(a/south australia/55/2014, wild type)b/phuket/3073/2013–like strain(b/utah/9/2014, wild type) - influenza, human; immunization - vaccines - prophylaxis of influenza for adults, especially in those who run an increased risk of associated complications.optaflu should be used in accordance to official guidance.

USA - engelsk - NLM (National Library of Medicine)

sanofi pasteur inc. - poliovirus type 1 antigen (formaldehyde inactivated) (unii: 0lvy784c09) (poliovirus type 1 antigen (formaldehyde inactivated) - unii:0lvy784c09), poliovirus type 2 antigen (formaldehyde inactivated) (unii: 23je9kdf4r) (poliovirus type 2 antigen (formaldehyde inactivated) - unii:23je9kdf4r), poliovirus type 3 antigen (formaldehyde inactivated) (unii: 459rom8m9m) (poliovirus type 3 antigen (formaldehyde inactivated) - unii:459rom8m9m) - poliovirus type 1 antigen (formaldehyde inactivated) 40 [d'ag'u] in 0.5 ml - ipol vaccine is indicated for active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus types 1, 2, and 3. (28) it is recommended that all infants (as young as 6 weeks of age), unimmunized children, and adolescents not previously immunized be vaccinated routinely against paralytic poliomyelitis. (29) following the eradication of poliomyelitis caused by wild poliovirus from the western hemisphere (including north and south america) (30), an ipv-only schedule was recommended to eliminate vapp. (7) all children should receive four doses of ipv at ages 2, 4, 6 to 18 months, and 4 to 6 years. opv is no longer available in the us and is not recommended for routine immunization. (7) previous clinical poliomyelitis (usually due to only a single poliovirus type) or incomplete immunization with opv are not contraindications to completing the primary series of immunization with ipol vaccine. children of all ages should have their immuni

USA - engelsk - NLM (National Library of Medicine)

teva women's health, inc. - human adenovirus e serotype 4 strain cl-68578 (unii: fkd3duk39i) (human adenovirus e serotype 4 strain cl-68578 - unii:fkd3duk39i) - human adenovirus e serotype 4 strain cl-68578 32000 [tcid_50] - adenovirus type 4 and type 7 vaccine, live, oral is a vaccine indicated for active immunization for the prevention of febrile acute respiratory disease caused by adenovirus type 4 and type 7. adenovirus type 4 and type 7 vaccine, live, oral is approved for use in military populations 17 through 50 years of age. adenovirus type 4 and type 7 vaccine, live, oral should not be administered to pregnant females [see pregnancy (8.1)] . it is not known whether adenovirus type 4 and type 7 vaccine, live, oral can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. naturally occurring infection with adenoviruses has been associated with fetal harm. pregnancy should be avoided for 6 weeks following receipt of vaccine. severe allergic reaction (e.g., anaphylaxis) to any component of adenovirus type 4 and type 7 vaccine, live, oral is a contraindication [see description (11)]. adenovirus type 4 and type 7 vaccine, live, oral should not be administered to individuals incapable of swa

USA - engelsk - NLM (National Library of Medicine)

seqirus inc. - influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (formaldehyde inactivated) (unii: q3p251c5mt) (influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) hemagglutinin antigen (formaldehyde inactivated) - unii:ld80h821hf) - influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (formaldehyde inactivated) 15 ug in 0.5 ml

USA - engelsk - NLM (National Library of Medicine)

protein sciences corporation - influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen (unii: 69h0yj871t) (influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen - unii:69h0yj871t) - influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen 45 ug in 0.5 ml

USA - engelsk - NLM (National Library of Medicine)

seqirus, inc. - influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (mdck cell derived, propiolactone inactivated) (unii: qwjhw3wexs) (influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) - unii:55qh9pjkdv) - influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (mdck cell derived, propiolactone inactivated) 15 ug in 0.5 ml

USA - engelsk - NLM (National Library of Medicine)

seqirus inc. - influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (propiolactone inactivated) (unii: v8pc20ubcn) (influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:wlsrj8jc6s) - influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (propiolactone inactivated) 15 ug in 0.5 ml

USA - engelsk - NLM (National Library of Medicine)

novartis vaccines and diagnostics limited - influenza a virus a/christchurch/16/2010 nib-74 (h1n1) antigen (propiolactone inactivated) (unii: h41xp0e6g8) (influenza a virus a/christchurch/16/2010 nib-74 (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:w3d48fdo26) - influenza a virus a/christchurch/16/2010 nib-74 (h1n1) hemagglutinin antigen (propiolactone inactivated) 15 ug in 0.5 ml

USA - engelsk - NLM (National Library of Medicine)

sanofi pasteur inc. - influenza a virus a/michigan/45/2015 x-275 (h1n1) antigen (formaldehyde inactivated) (unii: 8ksk0802bp) (influenza a virus a/michigan/45/2015 x-275 (h1n1) hemagglutinin antigen (formaldehyde inactivated) - unii:116749898h) - influenza a virus a/michigan/45/2015 x-275 (h1n1) hemagglutinin antigen (formaldehyde inactivated) 9 ug in 0.1 ml

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

surface antigen, inactivated - influenza virus surface antigens - suspension for injection